Journal article

The Safety of Influenza and Pertussis Vaccination in Pregnancy in a Cohort of Australian Mother-Infant Pairs, 2012-2015: The FluMum Study

Lisa McHugh, Helen S Marshall, Kirsten P Perrett, Terry Nolan, Nicholas Wood, Stephen B Lambert, Peter Richmond, Robert S Ware, Paula Binks, Michael J Binks, Ross M Andrews



Background: Inactivated influenza vaccine (IIV) and pertussis vaccination are recommended in pregnancy. Limited safety data exist for women who received IIV vaccine during the first trimester of pregnancy or received both vaccines in pregnancy. We assessed adverse birth outcomes between vaccinated and unvaccinated pregnancies. Methods: Among prospectively enrolled Australian "FluMum" participants (2012-2015), primary exposure was receipt and timing of IIV during pregnancy. Primary outcomes included preterm birth, low birthweight at term (LBWT), and small for gestational age (SGA). We compared birth outcomes for IIV in pregnancy with women unvaccinated in pregnancy using Cox proportional haza..

View full abstract


Awarded by National Health and Medical Research Council (NHMRC)

Awarded by NHMRC Early Career Fellowship

Awarded by NHMRC Career Development Fellowship

Awarded by NHMRC

Funding Acknowledgements

The FluMum Study is funded by the National Health and Medical Research Council (NHMRC) (Project Grant APP1020035). L. M. was supported by an Australian Postgraduate Award scholarship provided by Charles Darwin University and an Enhanced Living scholarship provided by Menzies School of Health Research as part of the Doctor of Philosophy program. K. P. P. was supported by an NHMRC Early Career Fellowship (APP1054394) and a Murdoch Children's Research Institute Career Development Award. N. W. and H. S. M. were supported by an NHMRC Career Development Fellowship (APP1063629 and APP1084951, respectively). S. B. L. is the recipient of an NHMRC Early Career Fellowship and a Children's Hospital Foundation Queensland Mid-career Fellowship. M. J. B. is an NHMRC Early Career Fellow (APP1088733).